Figure 4
Relative mRNA expressions of hypoxia inducible factor-1α (HIF1α, A), CCL2 (B), interleukin-1β (IL-1β, C), transforming growth factor-β1 (TGF-β1, D), connective tissue growth factor (CTGF, E), α-smooth muscle actin (α-SMA, F), collagen I (G), collagen III (H) and protein gene product 9.5 (PGP9.5, I) in the bladder of control, pBOO + PBS and pBOO + hAFSCs treatment. After hAFSCs treatment, the mRNA expressions of CTGF and α-SMA are improved at 2 and 6 weeks after pBOO, but HIF1α, CCL2, IL-1β, TGF-β1, collagen I and collagen III are improved only at 2 weeks after pBOO. The mRNA levels of PGP9.5 are improved after hAFSCs treatment only at 6 weeks after pBOO. *: P < 0.05 vs. control, #: P < 0.05 vs. pBOO + PBS. N = 6 in each time point.
